Lupin’s US Arm Secures 82% Stake in Kaveri Therapeutics for $1.6 Million, Bolstering Oncology Pipeline

Lupin Limited, through its wholly-owned U.S. subsidiary Lupin Inc. U.S.A. (LI), has announced the acquisition of an 82.2% equity stake in Kaveri Therapeutics, Inc., a U.S.-based clinical-stage oncology company. The strategic transaction, valued at US$1.6 million (approximately ₹13.6 crore), is aimed at accelerating the development of innovative cancer therapies and strengthening Lupin’s specialty pharmaceuticals portfolio.

The acquisition marks another important milestone in Lupin’s long-term strategy to expand its global oncology footprint through innovation-driven partnerships and targeted investments.

Lupin Expands Presence in Oncology

As part of the transaction, Lupin Inc. U.S.A. has granted Kaveri Therapeutics an exclusive perpetual license to develop two of its oncology drug candidates:

• LNP7457 (PRMT5 inhibitor)
• LNP8701 (SOS1 inhibitor)

In return, Lupin Inc. U.S.A. received 332,000 common shares of Kaveri Therapeutics, giving it a controlling 82.2% ownership stake in the company.

Additionally, Lupin will provide initial seed funding to support the advancement of these oncology programs through global clinical development while enabling Kaveri Therapeutics to raise additional capital for future growth.

Transaction Highlights

The key details of the acquisition include:

• Acquired Company: Kaveri Therapeutics, Inc., U.S.A.
• Lupin’s Stake: 82.2% equity ownership.
• Transaction Value: US$1.6 million (approximately ₹13.6 crore).
• Licensed Assets: LNP7457 (PRMT5) and LNP8701 (SOS1).
• Business Focus: Development of innovative therapies for solid tumors.
• Completion Date: July 20, 2026.

Focus on Next-Generation Cancer Therapies

Kaveri Therapeutics is a clinical-stage biotechnology company focused on developing targeted therapies for solid tumors, including:

• Lung cancer
• Pancreatic cancer
• Ovarian cancer
• Central nervous system (CNS)-related cancers
• Other difficult-to-treat malignancies

The licensed drug candidates target critical molecular pathways involved in cancer progression and represent promising additions to Lupin’s oncology research portfolio.

Strategic Importance for Lupin

The acquisition aligns with Lupin’s strategy of expanding its specialty pharmaceutical business through innovation and targeted collaborations.

By creating a dedicated oncology-focused entity, Lupin aims to accelerate the clinical development of its promising research assets while leveraging Kaveri Therapeutics’ specialized expertise in oncology drug development.

The transaction also allows Lupin to pursue future value creation through successful clinical trials, strategic partnerships, and potential commercialization opportunities in global markets.

Outlook

The acquisition of an 82.2% stake in Kaveri Therapeutics strengthens Lupin’s position in the rapidly growing oncology segment and reflects its continued investment in high-value specialty therapies.

With promising oncology programs, dedicated clinical development, and a focused strategy to address unmet medical needs in cancer treatment, the transaction has the potential to create long-term value for both patients and shareholders as Lupin expands its global specialty pharmaceuticals business.